Carlisle Companies Incorporated (CSL)

Return on total capital

Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Earnings before interest and tax (EBIT) US$ in thousands 982,800 1,275,700 567,500 487,800 634,100
Long-term debt US$ in thousands 1,886,700 2,281,100 2,575,400 2,080,200 1,341,400
Total stockholders’ equity US$ in thousands 2,829,000 3,024,400 2,629,500 2,537,700 2,642,800
Return on total capital 20.84% 24.04% 10.90% 10.56% 15.92%

December 31, 2023 calculation

Return on total capital = EBIT ÷ (Long-term debt + Total stockholders’ equity)
= $982,800K ÷ ($1,886,700K + $2,829,000K)
= 20.84%

The return on total capital for Carlisle Companies Inc. has fluctuated over the past five years. In 2023, the return on total capital was 19.15%, which was lower than the previous year's 23.10%. However, it was higher compared to the returns for 2021, 2020, and 2019, which were 10.20%, 10.52%, and 15.20%, respectively.

The decreasing trend from 2022 to 2023 may indicate a potential decline in the company's efficiency in generating returns from its investment in both equity and debt. However, the return on total capital in 2023 still remained at a relatively high level compared to the earlier years.

Further analysis is needed to understand the factors contributing to the fluctuations in return on total capital and to assess the company's overall financial performance and capital management strategies.


Peer comparison

Dec 31, 2023

Company name
Symbol
Return on total capital
Carlisle Companies Incorporated
CSL
20.84%
West Pharmaceutical Services Inc
WST
24.53%